Global Branded PAH Therapeutics Market (2023 Edition) - Analysis By Drug Class, Route of Administration, Distribution Channel, By Region, By Country: Market Insights and Forecast (2019-2029)

Report
250 Pages
November 2023
Region: Global
Azoth Analytics
ID: 5899399

The publisher has released a research report titled “Global Branded PAH Therapeutics Market (2023 Edition)” which provides a complete analysis of the Global Branded PAH Therapeutics industry in terms of market segmentation By Drug Class (Endothelin Receptor Antagonist (ERA's), TGF-β Ligand Traps and Soluble guanylate cyclase (sGC) stimulators, Prostacyclin Receptor Agonists, Others), By Route of Administration (Oral, Intravenous/Subcutaneous, Others), By Distribution Channel (Hospitals, Retail Pharmacies, Online Pharmacies), By Region (Americas , Europe, Asia-pacific, Middle-East & Africa), for the historical period of 2019-2022, the estimates of 2023 and the forecast period of 2024-2029.

The research report covers a detailed analysis of the regions (Americas, Europe, APAC, Middle East Africa) and 10 countries (United States, Canada, United Kingdom, Germany, France, Italy, China, Japan, India, South Korea). Additionally, the research report presents data including market size, yearly growth & potential analysis, the competitive study of market players, investment opportunities and demand forecast.

The research report also assesses growth indicators, restraints, supply and demand risk, and other important statistics, as well as a full assessment of current and future market trends that are relevant to the market evolution.

The Global Branded PAH Therapeutics Market is expected to generate USD 9868.66 million by the end of 2029, up from USD 6671.17 million in 2022. A favourable growth element for the global Branded PAH Therapeutics market is propelled by increasing prevalence, advancement in research and development, evolving treatment landscape and regulatory approvals. During the forecast period, 2024-2029, Global Branded PAH Therapeutics is expected to expand at a CAGR of 5.89%. The development of targeted therapies, including prostacyclin analogs, endothelin receptor antagonists, and tyrosine kinase inhibitors, has revolutionized the treatment of PAH. These therapies offer better disease management and outcomes, driving market growth.

Pulmonary hypertension is becoming an increasingly common global health issue, according to The Pulmonary Vascular Research Institute Pulmonary arterial hypertension (PAH), especially the idiopathic form, although still a rare disease with an incidence of 2-5 per million adults, is increasingly being diagnosed in elderly people. A growing understanding of PAH, along with improved diagnostic methods, has led to an increase in the diagnosed cases of PAH worldwide.

Ongoing research efforts to better understand the pathophysiology of PAH and to develop more effective treatments are a significant driver of the market. New drug discoveries and improved therapies drive branded PAH therapeutics growth. The development and approval of novel PAH medications, such as macitentan (Opsumit) and selexipag (Uptravi), are the results of continuous R&D efforts. These drugs have demonstrated improved efficacy and safety profiles.

Retail pharmacies are often widely distributed, making branded PAH medications more accessible to patients, including those in remote or rural areas. Increased accessibility helps ensure that patients have access to essential medications, reducing barriers to treatment. Also, retail pharmacies provide a convenient location for patients to fill initial prescriptions and receive refills of branded PAH therapeutics. This simplifies the medication acquisition process, supporting ongoing treatment.

Innovations in drug delivery systems, such as subcutaneous and implantable infusion pumps, provide a more convenient and continuous delivery of prostacyclin analogs, improving patient adherence and reducing the burden of intravenous administration. Advanced delivery systems enhance patient comfort and treatment adherence, leading to better control of PAH symptoms and improved patient outcomes.

Technological advancements have transformed the landscape of PAH diagnosis, treatment, and patient care. They have improved the accuracy and efficiency of diagnosis, enabled more personalized therapies, and enhanced the quality of life for PAH patients. Additionally, the integration of technology has the potential to drive further innovation in the field, improving outcomes for individuals living with PAH.

Scope of the Report

The report analyses the Branded PAH Therapeutics Market by Value (USD Million)
The report presents the analysis of Branded PAH Therapeutics Market for the historical period of 2019-2022, the estimated year 2023 and the forecast period of 2024-2029.
The report analyses the Branded PAH Therapeutics Market by Drug Class (Endothelin Receptor Antagonist (ERA's), TGF-β Ligand Traps and Soluble guanylate cyclase (sGC) stimulators, Prostacyclin Receptor Agonists, Others).
The report analyses the Branded PAH Therapeutics Market by Route of Administration (Oral, Intravenous/Subcutaneous, Others).
The report analyses the Branded PAH Therapeutics Market by Distribution Channel (Hospitals, Retail Pharmacies, Online Pharmacies).
The key insights of the report have been presented through the frameworks of SWOT and Porter’s Five Forces Analysis. Also, the attractiveness of the market has been presented by region, by services, by mode of operation & by end users.
Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.
The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include United Therapeutics, Johnson & Johnson, GlaxoSmithKline, Merck & Co., Inc., Gilead Sciences, Bayer AG, Pfizer, Eli Lilly and Company, Bristol-Myers Squibb Co., and CMP Pharma.

1. Market Background

1.1 Scope and Product Outlook
1.2 Executive Summary
1.3 Research Methodology

2. Strategic Recommendations

2.1 Rising number of lung infections caused by smoking and pollution
2.2 Improving healthcare infrastructure in developing nation

3. Global Branded PAH Therapeutics Market: Historic and Forecast

3.1 Impact Analysis of Macro Economic Factors on Global Branded PAH Therapeutics Market
3.2 Sales statistics of approved drugs
3.3 Status of Marketed and approved Branded PAH Drugs
3.4 PAH Patient and Therapy Landscape and Estimates
3.5 Global Branded PAH Therapeutics Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
3.6 Degree of Impact of Covid-19 on Branded PAH Therapeutics Market
3.7 Global Branded PAH Therapeutics Market Segmentation : By Drug Class
3.7.1 Global Branded PAH Therapeutics Market, By Drug Class Overview
3.7.2 Global Branded PAH Therapeutics Market Size, By Endothelin Receptor Antagonist (ERA's), By Value, 2019H-2029F (USD Million & CAGR)
3.7.3 Global Branded PAH Therapeutics Market Size, By TGF-ß Ligand Traps and Soluble guanylate cyclase (sGC) stimulators, By Value, 2019H-2029F (USD Million & CAGR)
3.7.4 Global Branded PAH Therapeutics Market Size, By Prostacyclin Receptor Agonists, By Value, 2019H-2029F (USD Million & CAGR)
3.7.5 Global Branded PAH Therapeutics Market Size, By Others, By Value, 2019H-2029F (USD Million & CAGR)
3.8 Global Branded PAH Therapeutics Market Segmentation : By Route of Administration
3.8.1 Global Branded PAH Therapeutics Market, By Route of Administration Overview
3.8.2 Global Branded PAH Therapeutics Market Size, By Oral, By Value, 2019H-2029F (USD Million & CAGR)
3.8.3 Global Branded PAH Therapeutics Market Size, By Intravenous/Subcutaneous, By Value, 2019H-2029F (USD Million & CAGR)
3.8.4 Global Branded PAH Therapeutics Market Size, By Others, By Value, 2019H-2029F (USD Million & CAGR)
3.9 Global Branded PAH Therapeutics Market Segmentation : By Distribution Channel
3.9.1 Global Branded PAH Therapeutics Market, By Distribution Channel Overview
3.9.2 Global Branded PAH Therapeutics Market Size, By Hospitals, By Value, 2019H-2029F (USD Million & CAGR)
3.9.3 Global Branded PAH Therapeutics Market Size, By Retail Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
3.9.4 Global Branded PAH Therapeutics Market Size, By Online Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)

4. Global Branded PAH Therapeutics Market, Region Analysis

4.1 Regional Coverage of the Study
4.2 Regional Snapshot

5. Americas Branded PAH Therapeutics Market: Historic and Forecast

5.1 Americas Branded PAH Therapeutics Market: Snapshot
5.2 Americas Branded PAH Therapeutics Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
5.3 Americas Branded PAH Therapeutics Market: Key Factors
5.4 Americas Branded PAH Therapeutics Market: Segment Analysis
5.5 Americas Branded PAH Therapeutics Market Segmentation : By Drug Class
5.5.1 Americas Branded PAH Therapeutics Market, By Drug Class Overview
5.5.2 Americas Branded PAH Therapeutics Market Size, By Endothelin Receptor Antagonist (ERA's), By Value, 2019H-2029F (USD Million & CAGR)
5.5.3 Americas Branded PAH Therapeutics Market Size, By TGF-ß Ligand Traps and Soluble guanylate cyclase (sGC) stimulators, By Value, 2019H-2029F (USD Million & CAGR)
5.5.4 Americas Branded PAH Therapeutics Market Size, By Prostacyclin Receptor Agonists, By Value, 2019H-2029F (USD Million & CAGR)
5.5.5 Americas Branded PAH Therapeutics Market Size, By Others, By Value, 2019H-2029F (USD Million & CAGR)
5.6 Americas Branded PAH Therapeutics Market Segmentation : By Route of Administration
5.6.1 Americas Branded PAH Therapeutics Market, By Route of Administration Overview
5.6.2 Americas Branded PAH Therapeutics Market Size, By Oral, By Value, 2019H-2029F (USD Million & CAGR)
5.6.3 Americas Branded PAH Therapeutics Market Size, By Intravenous/Subcutaneous, By Value, 2019H-2029F (USD Million & CAGR)
5.6.4 Americas Branded PAH Therapeutics Market Size, By Others, By Value, 2019H-2029F (USD Million & CAGR)
5.7 Americas Branded PAH Therapeutics Market Segmentation : By Distribution Channel
5.7.1 Americas Branded PAH Therapeutics Market, By Distribution Channel Overview
5.7.2 Americas Branded PAH Therapeutics Market Size, By Hospitals, By Value, 2019H-2029F (USD Million & CAGR)
5.7.3 Americas Branded PAH Therapeutics Market Size, By Retail Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
5.7.4 Americas Branded PAH Therapeutics Market Size, By Online Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
5.8 Americas Branded PAH Therapeutics Market Segmentation : By Country
5.8.1 Americas Branded PAH Therapeutics Market, By Country Overview
5.8.2 United States Branded PAH Therapeutics Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
5.8.2.1 United States Branded PAH Therapeutics Market, By Drug Class
5.8.2.2 United States Branded PAH Therapeutics Market, By Route of Administration
5.8.2.3 United States Branded PAH Therapeutics Market, By Distribution Channel
5.8.3 Canada Branded PAH Therapeutics Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
5.8.3.1 Canada Branded PAH Therapeutics Market, By Drug Class
5.8.3.2 Canada Branded PAH Therapeutics Market, By Route of Administration
5.8.3.3 Canada Branded PAH Therapeutics Market, By Distribution Channel
5.8.4 Rest of Americas Branded PAH Therapeutics Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
5.8.4.1 Rest of Americas Branded PAH Therapeutics Market, By Drug Class
5.8.4.2 Rest of Americas Branded PAH Therapeutics Market, By Route of Administration
5.8.4.3 Rest of Americas Branded PAH Therapeutics Market, By Distribution Channel

6. Europe Branded PAH Therapeutics Market: Historic and Forecast

6.1 Europe Branded PAH Therapeutics Market: Snapshot
6.2 Europe Branded PAH Therapeutics Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
6.3 Europe Branded PAH Therapeutics Market: Key Factors
6.4 Europe Branded PAH Therapeutics Market: Segment Analysis
6.5 Europe Branded PAH Therapeutics Market Segmentation : By Drug Class
6.5.1 Europe Branded PAH Therapeutics Market, By Drug Class Overview
6.5.2 Europe Branded PAH Therapeutics Market Size, By Endothelin Receptor Antagonist (ERA's), By Value, 2019H-2029F (USD Million & CAGR)
6.5.3 Europe Branded PAH Therapeutics Market Size, By TGF-ß Ligand Traps and Soluble guanylate cyclase (sGC) stimulators, By Value, 2019H-2029F (USD Million & CAGR)
6.5.4 Europe Branded PAH Therapeutics Market Size, By Prostacyclin Receptor Agonists, By Value, 2019H-2029F (USD Million & CAGR)
6.5.5 Europe Branded PAH Therapeutics Market Size, By Others, By Value, 2019H-2029F (USD Million & CAGR)
6.6 Europe Branded PAH Therapeutics Market Segmentatio : By Route of Administration
6.6.1 Europe Branded PAH Therapeutics Market, By Route of Administration Overview
6.6.2 Europe Branded PAH Therapeutics Market Size, By Oral, By Value, 2019H-2029F (USD Million & CAGR)
6.6.3 Europe Branded PAH Therapeutics Market Size, By Intravenous/Subcutaneous, By Value, 2019H-2029F (USD Million & CAGR)
6.6.4 Europe Branded PAH Therapeutics Market Size, By Others, By Value, 2019H-2029F (USD Million & CAGR)
6.7 Europe Branded PAH Therapeutics Market Segmentation: By Distribution Channel
6.7.1 Europe Branded PAH Therapeutics Market, By Distribution Channel Overview
6.7.2 Europe Branded PAH Therapeutics Market Size, By Hospitals, By Value, 2019H-2029F (USD Million & CAGR)
6.7.3 Europe Branded PAH Therapeutics Market Size, By Retail Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
6.7.4 Europe Branded PAH Therapeutics Market Size, By Online Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
6.8 Europe Branded PAH Therapeutics Market Segmentation: By Country
6.8.1 Europe Branded PAH Therapeutics Market, By Country Overview
6.8.2 Germany Branded PAH Therapeutics Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
6.8.2.1 Germany Branded PAH Therapeutics Market, By Drug Class
6.8.2.2 Germany Branded PAH Therapeutics Market, By Route of Administration
6.8.2.3 Germany Branded PAH Therapeutics Market, By Distribution Channel
6.8.3 United Kingdom Branded PAH Therapeutics Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
6.8.3.1 United Kingdom Branded PAH Therapeutics Market, By Drug Class
6.8.3.2 United Kingdom Branded PAH Therapeutics Market, By Route of Administration
6.8.3.2 United Kingdom Branded PAH Therapeutics Market, By Distribution Channel
6.8.4 France Branded PAH Therapeutics Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
6.8.4.1 France Branded PAH Therapeutics Market, By Drug Class
6.8.4.2 France Branded PAH Therapeutics Market, By Route of Administration
6.8.4.3 France Branded PAH Therapeutics Market, By Distribution Channel
6.8.5 Italy Branded PAH Therapeutics Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
6.8.5.1 Italy Branded PAH Therapeutics Market, By Drug Class
6.8.5.2 Italy Branded PAH Therapeutics Market, By Route of Administration
6.8.5.3 Italy Branded PAH Therapeutics Market, By Distribution Channel
6.8.6 Rest of Europe Branded PAH Therapeutics Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
6.8.6.1 Rest of Europe Branded PAH Therapeutics Market, By Route of Administration
6.8.6.2 Rest of Europe Branded PAH Therapeutics Market, By Drug Class
6.8.6.3 Rest of Europe Branded PAH Therapeutics Market, By Distribution Channel

7. Asia Pacific Branded PAH Therapeutics Market: Historic and Forecast

7.1 Asia Pacific Branded PAH Therapeutics Market: Snapshot
7.2 Asia Pacific Branded PAH Therapeutics Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
7.3 Asia Pacific Branded PAH Therapeutics Market: Key Factors
7.4 Asia Pacific Branded PAH Therapeutics Market: Segment Analysis
7.5 Asia Pacific Branded PAH Therapeutics Market Segmentation: By Drug Class
7.5.1 Asia Pacific Branded PAH Therapeutics Market, By Drug Class Overview
7.5.2 Asia Pacific Branded PAH Therapeutics Market Size, By Endothelin Receptor Antagonist (ERA's), By Value, 2019H-2029F (USD Million & CAGR)
7.5.3 Asia Pacific Branded PAH Therapeutics Market Size, By TGF-ß Ligand Traps and Soluble guanylate cyclase (sGC) stimulators, By Value, 2019H-2029F (USD Million & CAGR)
7.5.4 Asia Pacific Branded PAH Therapeutics Market Size, By Prostacyclin Receptor Agonists, By Value, 2019H-2029F (USD Million & CAGR)
7.5.5 Asia Pacific Branded PAH Therapeutics Market Size, By Others, By Value, 2019H-2029F (USD Million & CAGR)
7.6 Asia Pacific Branded PAH Therapeutics Market Segmentation : By Route of Administration
7.6.1 Asia Pacific Branded PAH Therapeutics Market, By Route of Administration Overview
7.6.2 Asia Pacific Branded PAH Therapeutics Market Size, By Oral, By Value, 2019H-2029F (USD Million & CAGR)
7.6.3 Asia Pacific Branded PAH Therapeutics Market Size, By Intravenous/Subcutaneous, By Value, 2019H-2029F (USD Million & CAGR)
7.6.4 Asia Pacific Branded PAH Therapeutics Market Size, By Others, By Value, 2019H-2029F (USD Million & CAGR)
7.7 Asia Pacific Branded PAH Therapeutics Market Segmentation : By Distribution Channel
7.7.1 Asia Pacific Branded PAH Therapeutics Market, By Distribution Channel Overview
7.7.2 Asia Pacific Branded PAH Therapeutics Market Size, By Hospitals, By Value, 2019H-2029F (USD Million & CAGR)
7.7.3 Asia Pacific Branded PAH Therapeutics Market Size, By Retail Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
7.7.4 Asia Pacific Branded PAH Therapeutics Market Size, By Online Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
7.8 Asia Pacific Branded PAH Therapeutics Market Segmentation : By Country
7.8.1 Asia Pacific Branded PAH Therapeutics Market, By Country Overview
7.8.2 China Branded PAH Therapeutics Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
7.8.2.1 China Branded PAH Therapeutics Market, By Drug Class
7.8.2.2 China Branded PAH Therapeutics Market, By Route of Administration
7.8.2.3 China Branded PAH Therapeutics Market, By Distribution Channel
7.8.3 Japan Branded PAH Therapeutics Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
7.8.3.1 Japan Branded PAH Therapeutics Market, By Drug Class
7.8.3.2 Japan Branded PAH Therapeutics Market, By Route of Administration
7.8.3.3 Japan Branded PAH Therapeutics Market, By Distribution Channel
7.8.4 India Branded PAH Therapeutics Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
7.8.4.1 India Branded PAH Therapeutics Market, By Drug Class
7.8.4.2 India Branded PAH Therapeutics Market, By Route of Administration
7.8.4.3 India Branded PAH Therapeutics Market, By Distribution Channel
7.8.5 South Korea Branded PAH Therapeutics Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
7.8.5.1 South Korea Branded PAH Therapeutics Market, By Route of Administration
7.8.5.2 South Korea Branded PAH Therapeutics Market, By Drug Class
7.8.5.3 South Korea Branded PAH Therapeutics Market, By Distribution Channel
7.8.6 Rest of Asia Pacific Branded PAH Therapeutics Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
7.8.6.1 Rest of Asia Pacific Branded PAH Therapeutics Market, By Drug Class
7.8.6.2 Rest of Asia Pacific Branded PAH Therapeutics Market, By Route of Administration
7.8.6.3 Rest of Asia Pacific Branded PAH Therapeutics Market, By Distribution Channel

8. Middle East & Africa Branded PAH Therapeutics Market: Historic and Forecast

8.1 Middle East and Africa Branded PAH Therapeutics Market: Snapshot
8.2 Middle East and Africa Branded PAH Therapeutics Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
8.3 Middle East and Africa Branded PAH Therapeutics Market: Key Factors
8.4 Middle East and Africa Branded PAH Therapeutics Market: Segment Analysis
8.5 Middle East and Africa Branded PAH Therapeutics Market Segmentation : By Drug Class
8.5.1 Middle East and Africa Branded PAH Therapeutics Market, By Drug Class Overview
8.5.2 Middle East and Africa Branded PAH Therapeutics Market Size, By Endothelin Receptor Antagonist (ERA's), By Value, 2019H-2029F (USD Million & CAGR)
8.5.3 Middle East and Africa Branded PAH Therapeutics Market Size, By TGF-ß Ligand Traps and Soluble guanylate cyclase (sGC) stimulators, By Value, 2019H-2029F (USD Million & CAGR)
8.5.4 Middle East and Africa Branded PAH Therapeutics Market, By Prostacyclin Receptor Agonists, By Value, 2019H-2029F (USD Million & CAGR)
8.5.5 Middle East and Africa Branded PAH Therapeutics Market Size, By Others, By Value, 2019H-2029F (USD Million & CAGR)
8.6 Middle East and Africa Branded PAH Therapeutics Market Segmentation : By Route of Administration
8.6.1 Middle East and Africa Branded PAH Therapeutics Market, By Route of Administration Overview
8.6.2 Middle East and Africa Branded PAH Therapeutics Market Size, By Oral, By Value, 2019H-2029F (USD Million & CAGR)
8.6.3 Middle East and Africa Branded PAH Therapeutics Market Size, By Intravenous/Subcutaneous, By Value, 2019H-2029F (USD Million & CAGR)
8.6.4 Middle East and Africa Branded PAH Therapeutics Market, By Others years, By Value, 2019H-2029F (USD Million & CAGR)
8.7 Middle East and Africa Branded PAH Therapeutics Market Segmentation : By Distribution Channel
8.7.1 Middle East and Africa Branded PAH Therapeutics Market, By Distribution Channel Overview
8.7.2 Middle East and Africa Branded PAH Therapeutics Market Size, By Hospitals, By Value, 2019H-2029F (USD Million & CAGR)
8.7.3 Middle East and Africa Branded PAH Therapeutics Market, By Retail Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
8.7.4 Middle East and Africa Branded PAH Therapeutics Market, By Online Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)

9. Market Dynamics

9.1 Impact assessment of Market Dynamics on Global Branded PAH Therapeutics Market
9.2 Drivers
9.3 Restraints
9.4 Trends

10. Industry Ecosystem Analysis

10.1 Porter Analysis

11. Competitive Landscape

11. Competitive Positioning
11.1 Companies’ Product Positioning
11.2 Market Share of Leading Companies
11.3 Company Profiling
11.3.1 United Therapeutics
11.3.2 Johnson & Johnson
11.4.3 GlaxoSmithKline
11.3.4 Merck & Co., Inc.
11.3.5 Gilead Sciences
11.3.6 Bayer AG
11.3.7 Pfizer
11.3.8 Eli Lilly and Company
11.3.9 Bristol-Myers Squibb Co.
11.3.10 CMP Pharma

12. About the Publisher and Disclaimer

List of Figures

Figure 1: Sales of approved drugs within the Global Branded PAH Therapeutics Market, 2021 (%)
Figure 2: PAH Patient and Therapy Landscape and Estimates
Figure 3: Global Branded PAH Therapeutics Market Size, By Value, 2019-2022 (USD Million)
Figure 4: Global Branded PAH Therapeutics Market Size, By Value, 2023-2029 (USD Million)
Figure 5: Global Branded PAH Therapeutics Market Share, By Drug Class, 2022 (%)
Figure 6: Global Branded PAH Therapeutics Market Size, By Endothelin Receptor Antagonist (ERA's), By Value, 2019H-2029F (USD Million & CAGR)
Figure 7: Global Branded PAH Therapeutics Market Absolute Opportunity, By Endothelin Receptor Antagonist (ERA's), 2019H-2029F (USD Million)
Figure 8: Global Branded PAH Therapeutics Market Size, By TGF-ß Ligand Traps and Soluble guanylate cyclase (sGC) stimulators , By Value, 2019H-2029F (USD Million & CAGR)
Figure 9: Global Branded PAH Therapeutics Market Absolute Opportunity, By TGF-ß Ligand Traps and Soluble guanylate cyclase (sGC) stimulators , 2019H-2029F (USD Million)
Figure 10: Global Branded PAH Therapeutics Market Size, By Prostacyclin Receptor Agonists, By Value, 2019H-2029F (USD Million & CAGR)
Figure 11: Global Branded PAH Therapeutics Market Absolute Opportunity, By Prostacyclin Receptor Agonists, 2019H-2029F (USD Million)
Figure 12: Global Branded PAH Therapeutics Market Size, By Others, By Value, 2019H-2029F (USD Million & CAGR)
Figure 13: Global Branded PAH Therapeutics Market Absolute Opportunity, By Others, 2019H-2029F (USD Million)
Figure 14: Global Branded PAH Therapeutics Market Size, By Oral, By Value, 2019H-2029F (USD Million & CAGR)
Figure 15: Global Branded PAH Therapeutics Market Absolute Opportunity, By Oral, 2019H-2029F (USD Million)
Figure 16: Global Branded PAH Therapeutics Market Size, By Intravenous/Subcutaneous, By Value, 2019H-2029F (USD Million & CAGR)
Figure 17: Global Branded PAH Therapeutics Market Absolute Opportunity, By Intravenous/Subcutaneous, 2019H-2029F (USD Million)
Figure 18: Global Branded PAH Therapeutics Market Size, By Others , By Value, 2019H-2029F (USD Million & CAGR)
Figure 19: Global Branded PAH Therapeutics Market Absolute Opportunity, By Others, 2019H-2029F (USD Million)
Figure 20: Global Branded PAH Therapeutics Market Size, By Hospitals, By Value, 2019H-2029F (USD Million & CAGR)
Figure 21: Global Branded PAH Therapeutics Market Absolute Opportunity, By Hospitals, 2019H-2029F (USD Million)
Figure 22: Global Branded PAH Therapeutics Market Size, By Retail Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
Figure 23: Global Branded PAH Therapeutics Market Absolute Opportunity, By Retail Pharmacies, 2019H-2029F (USD Million)
Figure 24: Global Branded PAH Therapeutics Market Size, By Online Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
Figure 25: Global Branded PAH Therapeutics Market Absolute Opportunity, By Online Pharmacies, 2019H-2029F (USD Million)
Figure 26: Americas Branded PAH Therapeutics Market Size, By Value, 2019H-2029F (USD Million)
Figure 27: Americas Branded PAH Therapeutics Market Share, By Drug Class, 2022 (%)
Figure 28: Americas Branded PAH Therapeutics Market , By Endothelin Receptor Antagonist (ERA's), By Value, 2019H-2029F (USD Million & CAGR)
Figure 29: Americas Branded PAH Therapeutics Market, By TGF-ß Ligand Traps and Soluble guanylate cyclase (sGC) stimulators, By Value, 2019H-2029F (USD Million & CAGR)
Figure 30: Americas Branded PAH Therapeutics Market , By Prostacyclin Receptor Agonists, By Value, 2019H-2029F (USD Million & CAGR)
Figure 31: Americas Branded PAH Therapeutics Market , By Others, By Value, 2019H-2029F (USD Million & CAGR)
Figure 32: Americas Branded PAH Therapeutics Market , By Oral, By Value, 2019H-2029F (USD Million & CAGR)
Figure 33: Americas Branded PAH Therapeutics Market , By Intravenous/Subcutaneous, By Value, 2019H-2029F (USD Million & CAGR)
Figure 34: Americas Branded PAH Therapeutics Market, By Others, By Value, 2019H-2029F (USD Million & CAGR)
Figure 35: Americas Branded PAH Therapeutics Market , By Hospitals, By Value, 2019H-2029F (USD Million & CAGR)
Figure 36: Americas Branded PAH Therapeutics Market , By Retail Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
Figure 37: Americas Branded PAH Therapeutics Market , By Online Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
Figure 38: United States Branded PAH Therapeutics Market, By Value, 2019H-2029F (USD Million & CAGR)
Figure 39: United States Branded PAH Therapeutics Market Value, By Route of Administration, 2022 (USD Million)
Figure 40: United States Branded PAH Therapeutics Market Share, By Drug Class, By Value, 2022 (%)
Figure 41: United States Branded PAH Therapeutics Market Share, By Route of Administration, By Value, 2022 (%)
Figure 42: United States Branded PAH Therapeutics Market Share, By Distribution Channel, By Value, 2022 (%)
Figure 43: Canada Branded PAH Therapeutics Market, By Value, 2019H-2029F (USD Million & CAGR)
Figure 44: Canada Branded PAH Therapeutics Market Value, By Route of Administration,, 2022 (USD Million)
Figure 45: Canada Branded PAH Therapeutics Market Share, By Drug Class, By Value, 2022 (%)
Figure 46: Canada Branded PAH Therapeutics Market Share, By Route of Administration, By Value, 2022 (%)
Figure 47: Canada Branded PAH Therapeutics Market Share, By Distribution Channel, By Value, 2022 (%)
Figure 48: Rest of Americas Branded PAH Therapeutics Market , By Value, 2019H-2029F (USD Million & CAGR)
Figure 49: Rest of Americas Branded PAH Therapeutics Market Value, By Route of Administration, 2022 (USD Million)
Figure 50: Rest of Americas Branded PAH Therapeutics Market Share, By Drug Class, By Value, 2022 (%)
Figure 51: Rest of Americas Branded PAH Therapeutics Market Share, By Route of Administration, By Value, 2022 (%)
Figure 52: Rest of Americas Branded PAH Therapeutics Market Share, By Distribution Channel, By Value, 2022 (%)
Figure 53: Europe Branded PAH Therapeutics Market Size, By Value, 2019H-2029F (USD Million)
Figure 54: Europe Branded PAH Therapeutics Market Share, By Drug Class, 2022 (%)
Figure 55: Europe Branded PAH Therapeutics Market , By Endothelin Receptor Antagonist (ERA's), By Value, 2019H-2029F (USD Million & CAGR)
Figure 56: Europe Branded PAH Therapeutics Market, By TGF-ß Ligand Traps and Soluble guanylate cyclase (sGC) stimulators, By Value, 2019H-2029F (USD Million & CAGR)
Figure 57: Europe Branded PAH Therapeutics Market , By Prostacyclin Receptor Agonists, By Value, 2019H-2029F (USD Million & CAGR)
Figure 58: Europe Branded PAH Therapeutics Market , By Others, By Value, 2019H-2029F (USD Million & CAGR)
Figure 59: Europe Branded PAH Therapeutics Market , By Oral, By Value, 2019H-2029F (USD Million & CAGR)
Figure 60: Europe Branded PAH Therapeutics Market , By Intravenous/Subcutaneous, By Value, 2019H-2029F (USD Million & CAGR)
Figure 61: Europe Branded PAH Therapeutics Market, By Others, By Value, 2019H-2029F (USD Million & CAGR)
Figure 62: Europe Branded PAH Therapeutics Market , By Hospitals, By Value, 2019H-2029F (USD Million & CAGR)
Figure 63: Europe Branded PAH Therapeutics Market , By Retail Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
Figure 64: Europe Branded PAH Therapeutics Market , By Online Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
Figure 65: Germany Branded PAH Therapeutics Market, By Value, 2019H-2029F (USD Million & CAGR)
Figure 66: Germany Branded PAH Therapeutics Market Value, By Route of Administration, 2022 (USD Million)
Figure 67: Germany Branded PAH Therapeutics Market Share, By Drug Class, By Value, 2022 (%)
Figure 68: Germany Branded PAH Therapeutics Market Share, By Route of Administration, By Value, 2022 (%)
Figure 69: Germany Branded PAH Therapeutics Market Share, By Distribution Channel, By Value, 2022 (%)
Figure 70: United Kingdom Branded PAH Therapeutics Market, By Value, 2019H-2029F (USD Million & CAGR)
Figure 71: United Kingdom Branded PAH Therapeutics Market Value, By Route of Administration, 2022 (USD Million)
Figure 72: United Kingdom Branded PAH Therapeutics Market Share, By Drug Class, By Value, 2022 (%)
Figure 73: United Kingdom Branded PAH Therapeutics Market Share, By Route of Administration, By Value, 2022 (%)
Figure 74: United Kingdom Branded PAH Therapeutics Market Share, By Distribution Channel, By Value, 2022 (%)
Figure 75: France Branded PAH Therapeutics Market, By Value, 2019H-2029F (USD Million & CAGR)
Figure 76: France Branded PAH Therapeutics Market Value, By Route of Administration, 2022 (USD Million)
Figure 77: France Branded PAH Therapeutics Market Share, By Drug Class, By Value, 2022 (%)
Figure 78: France Branded PAH Therapeutics Market Share, By Route of Administration, By Value, 2022 (%)
Figure 79: France Branded PAH Therapeutics Market Share, By Distribution Channel, By Value, 2022 (%)
Figure 80: Italy Branded PAH Therapeutics Market, By Value, 2019H-2029F (USD Million & CAGR)
Figure 81: Italy Branded PAH Therapeutics Market Value, By Route of Administration, 2022 (USD Million)
Figure 82: Italy Branded PAH Therapeutics Market Share, By Drug Class, By Value, 2022 (%)
Figure 83: Italy Branded PAH Therapeutics Market Share, By Route of Administration, By Value, 2022 (%)
Figure 84: Italy Branded PAH Therapeutics Market Share, By Distribution Channel, By Value, 2022 (%)
Figure 85: Rest of Europe Branded PAH Therapeutics Market , By Value, 2019H-2029F (USD Million & CAGR)
Figure 86: Rest of Europe Branded PAH Therapeutics Market Value, By Route of Administration, 2022 (USD Million)
Figure 87: Rest of Europe Branded PAH Therapeutics Market Share, By Drug Class, By Value, 2022 (%)
Figure 88: Rest of Europe Branded PAH Therapeutics Market Share, By Route of Administration, By Value, 2022 (%)
Figure 89: Rest of Europe Branded PAH Therapeutics Market Share, By Distribution Channel, By Value, 2022 (%)
Figure 90: Asia-Pacific Branded PAH Therapeutics Market Size, By Value, 2019H-2029F (USD Million)
Figure 91: Asia-Pacific Branded PAH Therapeutics Market Share, By Drug Class, 2022 (%)
Figure 92: Asia-Pacific Branded PAH Therapeutics Market , By Endothelin Receptor Antagonist (ERA's), By Value, 2019H-2029F (USD Million & CAGR)
Figure 93: Asia-Pacific Branded PAH Therapeutics Market, By TGF-ß Ligand Traps and Soluble guanylate cyclase (sGC) stimulators, By Value, 2019H-2029F (USD Million & CAGR)
Figure 94: Asia-Pacific Branded PAH Therapeutics Market , By Prostacyclin Receptor Agonists, By Value, 2019H-2029F (USD Million & CAGR)
Figure 95: Asia-Pacific Branded PAH Therapeutics Market , By Others, By Value, 2019H-2029F (USD Million & CAGR)
Figure 96: Asia-Pacific Branded PAH Therapeutics Market , By Oral, By Value, 2019H-2029F (USD Million & CAGR)
Figure 97: Asia-Pacific Branded PAH Therapeutics Market , By Intravenous/Subcutaneous, By Value, 2019H-2029F (USD Million & CAGR)
Figure 98: Asia-Pacific Branded PAH Therapeutics Market, By Others, By Value, 2019H-2029F (USD Million & CAGR)
Figure 99: Asia-Pacific Branded PAH Therapeutics Market , By Hospitals, By Value, 2019H-2029F (USD Million & CAGR)
Figure 100: Asia-Pacific Branded PAH Therapeutics Market , By Retail Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
Figure 101: Asia-Pacific Branded PAH Therapeutics Market , By Online Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
Figure 102: China Branded PAH Therapeutics Market, By Value, 2019H-2029F (USD Million & CAGR)
Figure 103: China Branded PAH Therapeutics Market Value, By Route of Administration, 2022 (USD Million)
Figure 104: China Branded PAH Therapeutics Market Share, By Drug Class, By Value, 2022 (%)
Figure 105: China Branded PAH Therapeutics Market Share, By Route of Administration, By Value, 2022 (%)
Figure 106: China Branded PAH Therapeutics Market Share, By Distribution Channel, By Value, 2022 (%)
Figure 107: Japan Branded PAH Therapeutics Market, By Value, 2019H-2029F (USD Million & CAGR)
Figure 108: Japan Branded PAH Therapeutics Market Value, By Route of Administration, 2022 (USD Million)
Figure 109: Japan Branded PAH Therapeutics Market Share, By Drug Class, By Value, 2022 (%)
Figure 110: Japan Branded PAH Therapeutics Market Share, By Route of Administration, By Value, 2022 (%)
Figure 111: Japan Branded PAH Therapeutics Market Share, By Distribution Channel, By Value, 2022 (%)
Figure 112: India Branded PAH Therapeutics Market, By Value, 2019H-2029F (USD Million & CAGR)
Figure 113: India Branded PAH Therapeutics Market Value, By Route of Administration, 2022 (USD Million)
Figure 114: India Branded PAH Therapeutics Market Share, By Drug Class, By Value, 2022 (%)
Figure 115: India Branded PAH Therapeutics Market Share, By Route of Administration, By Value, 2022 (%)
Figure 116: India Branded PAH Therapeutics Market Share, By Distribution Channel, By Value, 2022 (%)
Figure 117: South Korea Branded PAH Therapeutics Market, By Value, 2019H-2029F (USD Million & CAGR)
Figure 118: South Korea Branded PAH Therapeutics Market Value, By Route of Administration, 2022 (USD Million)
Figure 119: South Korea Branded PAH Therapeutics Market Share, By Drug Class, By Value, 2022 (%)
Figure 120: South Korea Branded PAH Therapeutics Market Share, By Route of Administration, By Value, 2022 (%)
Figure 121: South Korea Branded PAH Therapeutics Market Share, By Distribution Channel, By Value, 2022 (%)
Figure 122: Rest of Asia-Pacific Branded PAH Therapeutics Market, By Value, 2019H-2029F (USD Million & CAGR)
Figure 123: Rest of Asia-Pacific Branded PAH Therapeutics Market Value, By Route of Administration, 2022 (USD Million)
Figure 124: Rest of Asia-Pacific Branded PAH Therapeutics Market Share, By Drug Class, By Value, 2022 (%)
Figure 125: Rest of Asia-Pacific Branded PAH Therapeutics Market Share, By Drug Class, By Value, 2022 (%)
Figure 126: Rest of Asia-Pacific Branded PAH Therapeutics Market Share, By Distribution Channel, By Value, 2022 (%)
Figure 127: Middle East and Africa Branded PAH Therapeutics Market Size, By Value, 2019H-2029F (USD Million)
Figure 128: Middle East and Africa Branded PAH Therapeutics Market Share, By Drug Class, 2022 (%)
Figure 129: Middle East and Africa Branded PAH Therapeutics Market , By Endothelin Receptor Antagonist (ERA's), By Value, 2019H-2029F (USD Million & CAGR)
Figure 130: Middle East and Africa Branded PAH Therapeutics Market, By TGF-ß Ligand Traps and Soluble guanylate cyclase (sGC) stimulators, By Value, 2019H-2029F (USD Million & CAGR)

Table Information

Report Attribute	Details
No. of Pages	250
Published	November 2023
Forecast Period	2024 - 2029
Estimated Market Value ( USD ) in 2024	$ 7.41 Billion
Forecasted Market Value ( USD ) by 2029	$ 9.87 Billion
Compound Annual Growth Rate	5.8%
Regions Covered	Global

PURCHASE OPTIONS

Single User License PDF And Excel

Enterprise License PDF And Excel

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is a single user license, allowing one user access to the product.	€2365EUR$2,450USD£2,028GBP
ENTERPRISE LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is an enterprise license, allowing all employees within your organization access to the product.	€2847EUR$2,950USD£2,442GBP

Scope of the Report

Table of Contents

Table Information

Related Topics

Related Reports

Global Pulmonary Arterial Hypertension Market: Analysis By Drug Class, By Type, By Route of Administration, By Distribution Channel, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2028

Pulmonary Arterial Hypertension Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

Pulmonary Arterial Hypertension Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Global Pulmonary Arterial Hypertension Market (2023-2028) Competitive Analysis, Impact of Covid-19, Impact of Economic Slowdown & Impending Recession, Ansoff Analysis

Global Pulmonary Arterial Hypertension Market by Drug Class (Calcium Channel Blocker, Endothelin Receptor Antagonists, Phosphodiesterase 5), Distribution (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) - Forecast 2024-2030